NABOTA
DEAD

Serial Number

85902409

Owner

DAEWOONG PHARMACEUTICAL CO., LTD.

Attorney

John M. Kim

Filing Date

Apr 12, 2013

Add to watchlist:

No watchlists yet
View on USPTO

NABOTA Trademark

Serial Number: 85902409 • Registration: 4535957

NABOTA is a trademark filed by DAEWOONG PHARMACEUTICAL CO., LTD. on April 12, 2013. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

DAEWOONG PHARMACEUTICAL CO., LTD. (12 trademarks)

35-14, Jeyakgongdan 4-gil,

Entity Type: 03

Trademark Details

Filing Date

April 12, 2013

Registration Date

May 27, 2014

Published for Opposition

March 11, 2014

Cancellation Date

January 14, 2021

Goods & Services

Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment; pharmaceutical preparations for diagnosis; dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for chemical disorder treatment

Filing History

NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED
Jan 15, 2021 NCS7
CANCELLED SECTION 7-TOTAL
Jan 14, 2021 C7..
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 8, 2021 APRE
REQUEST FOR SECT 7 TOTAL SURRENDER FILED
Oct 19, 2020 C7RF
TEAS SECTION 7 SURRENDER RECEIVED
Oct 19, 2020 ES7S
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 19, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 19, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 19, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 19, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 19, 2020 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 27, 2019 REM1
REGISTERED-PRINCIPAL REGISTER
May 27, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 11, 2014 NPUB
PUBLISHED FOR OPPOSITION
Mar 11, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 4, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 29, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2014 CRFA
ASSIGNED TO LIE
Jan 21, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 30, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 30, 2013 GNRN
NON-FINAL ACTION E-MAILED
Jul 30, 2013 GNRT
NON-FINAL ACTION WRITTEN
Jul 30, 2013 CNRT
ASSIGNED TO EXAMINER
Jul 29, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 18, 2013 NWOS
NEW APPLICATION ENTERED
Apr 16, 2013 NWAP